Loratadine (Claritin) is a second-generation H1 antihistamine used to relieve seasonal and perennial allergic rhinitis and chronic hives in adults and children 2 years and older. It works by competitively blocking histamine H1 receptors on peripheral tissues, reducing sneezing, runny nose, and itching without causing significant sedation — it achieves less than 10% CNS H1 receptor occupancy due to low lipophilicity and active efflux by P-glycoprotein. Side effects are minimal, with rare headache or dry mouth. Rated Pregnancy Category B, it is considered genuinely non-drowsy at standard doses and is the preferred antihistamine for daytime use and in patients who drive.
Loratadine
Uses & FDA Indications
Loratadine is an FDA-approved second-generation antihistamine used to relieve symptoms of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in adults and children 2 years and older. It is one of the most widely used antihistamines worldwide and is available over-the-counter without a prescription.
FDA-approved indications include: seasonal allergic rhinitis (relief of sneezing, runny nose, itchy or watery eyes, and itching of the nose and throat), perennial allergic rhinitis (year-round allergy symptoms), and chronic idiopathic urticaria (hives and associated itching). It is particularly well-suited for patients who require daytime allergy control without any sedation.
Loratadine is widely preferred for daytime use, for patients who drive or operate machinery, for the elderly, and during pregnancy (Category B). It is also frequently used in children, where sedation from antihistamines is a particular concern for school performance and safety.
How It Works
Loratadine is a selective, long-acting peripheral H1 receptor antagonist. It competitively blocks histamine H1 receptors, preventing histamine from binding and triggering the allergic cascade: vasodilation, increased vascular permeability, bronchoconstriction, and the characteristic itching, sneezing, and nasal congestion of allergic reactions.
What distinguishes loratadine from first-generation antihistamines is its pharmacokinetic profile: it has low lipophilicity and is a substrate of the efflux transporter P-glycoprotein, which actively pumps it out of the central nervous system. As a result, loratadine achieves minimal brain penetration at therapeutic doses, producing H1 receptor occupancy in the CNS of less than 10% — compared to 50–70% for diphenhydramine. This is why loratadine is considered genuinely non-sedating for the large majority of patients.
Loratadine is metabolized in the liver by CYP3A4 and CYP2D6 to its active metabolite, desloratadine (sold separately as Clarinex). Desloratadine is actually more potent as an H1 antagonist and has a longer half-life (~27 hours) than the parent drug. Much of loratadine's duration of action reflects desloratadine's contribution — which is why once-daily dosing provides 24-hour coverage despite the parent compound's shorter half-life.
Side Effects
Common
- Headache — most commonly reported side effect; generally mild
- Dry mouth — rare at standard doses; far less anticholinergic than first-generation agents
- Fatigue — very rare; among the lowest rates of any antihistamine
- Nausea, stomach upset — uncommon; typically mild and transient
- Nervousness or insomnia — rare, primarily in children
Serious (Rare)
- Hypersensitivity / allergic reactions — rare; includes rash, urticaria, angioedema, anaphylaxis in hypersensitive individuals
- Hepatic impairment concerns — loratadine is extensively metabolized in the liver; accumulation can occur in patients with significant hepatic impairment, potentially intensifying effects
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| CYP3A4 Inhibitors (ketoconazole, erythromycin, clarithromycin, grapefruit juice) | Inhibition of CYP3A4 reduces loratadine's first-pass metabolism, increasing plasma levels of loratadine and desloratadine. Although higher concentrations can occur, clinical significance is minimal because neither loratadine nor desloratadine prolongs the QT interval at these elevated levels, and CNS effects remain low. | Minor — generally not clinically significant; monitor if concerned about side effects |
| CYP2D6 Inhibitors (fluoxetine, paroxetine, bupropion) | Similar to CYP3A4 inhibition — may increase loratadine levels modestly. Combined inhibition of both pathways (e.g., ketoconazole + paroxetine) would have greater effect on exposure but remains clinically low-risk. | Minor — not clinically significant in most patients |
| Alcohol | Unlike first-generation antihistamines, loratadine does not meaningfully potentiate alcohol-related sedation. Clinical studies have confirmed minimal additive CNS depression at standard doses. | Minimal — loratadine is one of the safest antihistamines with alcohol, though moderate alcohol use is not encouraged |
| Other Antihistamines | Combining multiple H1 antihistamines does not increase efficacy (same receptor target) but may increase side effects including dry mouth and sedation. No benefit to combination use. | Not recommended — no pharmacological rationale |
Warnings & Contraindications
Contraindications
- Hypersensitivity to loratadine or any component of the formulation
Hepatic Impairment
Because loratadine is extensively metabolized by the liver, patients with significant hepatic impairment clear the drug more slowly. Reduced dosing frequency is recommended in patients with severe hepatic impairment (e.g., alternate-day dosing instead of daily). Patients with mild-to-moderate liver disease may use standard dosing with monitoring.
Pregnancy and Lactation
Loratadine is Pregnancy Category B, meaning animal studies have not shown fetal harm and no adequate human studies have demonstrated harm. It is generally considered one of the safer antihistamine options during pregnancy. Loratadine and desloratadine are excreted in breast milk in small amounts; caution is advised in nursing, though significant neonatal sedation is unlikely given the drug's low CNS penetration.
Check for interactions between loratadine and your other medications.
Check Drug Interactions →Frequently Asked Questions
Is Claritin non-drowsy?
Loratadine (Claritin) is considered the least sedating among the commonly used oral antihistamines. It has very low lipophilicity and is actively pumped out of the brain by P-glycoprotein, resulting in minimal CNS penetration. In clinical trials at standard doses, loratadine showed drowsiness rates comparable to placebo — making it genuinely non-drowsy for the vast majority of people. This distinguishes it from cetirizine, which causes noticeable drowsiness in 10–15% of users.
How long does Claritin last?
Loratadine has a half-life of approximately 8–12 hours, and its active metabolite desloratadine has a half-life of about 27 hours. Together, this provides approximately 24 hours of antihistamine coverage with a single daily dose — which is why it is marketed as a once-daily medication. Antihistamine effects persist even after plasma levels begin to decline because of tight receptor binding. Most people notice symptom relief beginning within 1–3 hours of the first dose.
Can you take Claritin and Zyrtec together?
Combining loratadine and cetirizine is generally not recommended as a standard approach and is not an FDA-approved combination. Both are H1 antihistamines working at the same receptor — combining them does not double the antihistamine effect but does increase the risk of side effects, particularly sedation. If one antihistamine is not providing adequate symptom control, the right approach is to consult a healthcare provider about alternatives (such as adding an intranasal steroid, switching to fexofenadine, or addressing the underlying allergic trigger) rather than combining two antihistamines.